medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2007, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2007; 5 (1)

Granuloma due to Candida albicans in a diabetic patient. A case report

Palacios YE, Villanueva RJ, Fernández R, Arenas R

Language: Spanish
References: 44
Page: 44-49
PDF size: 310.05 Kb.


ABSTRACT

Granuloma due to Candida SP is a mucocutaneous infection more frequently observed in children. The main affected areas are face, oral mucosa, scalp and nails. Amphotericin B is an effective treatment.
We report a 41-year-old male with diabetes mellitus type 2, with two nodular skin lesions affecting the xiphoid appendix and the right hypocondrial area. Candida Albicans was isolated and the cytology test showed a granulomatous inflammatory reaction. In the biopsy with PAS, fungal hyphas were found. An important amelioration was observed with amphotericin B and itraconazol.


REFERENCES

  1. Rowell JL. Mucocutaneous candidiasis. Semin Perinatol 2003; 27 (5): 406-13

  2. Kugelman T, Derek J, Harrel R. Candida granuloma with epidermophytosis. Arch Dermatol 1963; 88: 150-157

  3. Kirkpatrick CH, Rich RR, Benett JE. Chronic mucocutaneous candidosis: Model building in cellular immunity. Ann Intern Med 1971; 74: 955-978

  4. Anstey A, Spickett G, Beechery-Newman N. A case of candidal umbilical granuloma. Br J Dermatol 1991: 124: 475-478

  5. Chiu SJ. Chronic mucocutaneous candidiasis in a 6-year-old boy. J Microbiol Immunol Infect 2004; 37 (3): 196-199

  6. Haynes K. Virulence in Candida species. Review Trends Microbiol. 2001; 12 (9): 591-595

  7. Drohuet E. Candidosis mucocutánea. Med Micol 2000; 8: 571-583

  8. Van G. Candida specific interferon gamma deficiency and toll like receptor polymorphisms in patients with chronic mucocutaneous candidiasis. Neth J Med 2003; 61 (11): 365-369

  9. Durandy A, Fisher A, Ledeist F. Mannan-specific and mannan induced T-cell suppressive activity in patients with chronic mucocutaneous candidosis. J Clin Immunol 1987; 7: 400-408

  10. Fisher A, Ballet J, Griscelli C. Specific inhibition of in vitro Candida induced lymphocytes proliferation by polysaccharides antigens present in the serum of patients with chronic mucocutaneous candidiasis. J Clin Invest 1978; 62: 1005-1013

  11. Buckeley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobinemia E and undue susceptibility to infection. Pediatrics 1972; 49: 59-70

  12. Buckley RH, Lucas ZJ, Hattler BG et al. Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: Immunological reconstitution by allogenic bone marrow. Clin Exp Immunol 1968; 3: 15-20

  13. Hill HR, Ochs HD, Quie P, et al. Defect in neutropenic granulocyte chemotaxis in Job’s syndrome of recurrent “cold” staphylococcal abscess. Lancet 1974; 2: 617-619

  14. López J. Mucocutaneous candidiasis as first manifestation of autoimmune polyglandular syndrome type. J Dent Child 2005; 72 (1): 21-4

  15. Myhre AG. Chronic mucocutaneous candidiasis and primary hypothyroidism in two families. Eur J Pediatr 2004; 163 (10): 604-611

  16. De Padova S, Chérie M, Kantor R. Candidiasis endocrinopathy syndrome. Arch Dermatol 1994; 130: 19-22

  17. Papazian C, Koch R. Monilia granuloma with hypothyroidism: Report of a case treated with amphotericin B. N Engl J Med 1960; 262: 16-18

  18. Lingelbach A. Chronic mucocutaneous candidosis with severe esophageal constricture. Mycoses 2003; 46: S 15-8

  19. Sathishkumar T. Chronic mucocutaneous candidiasis in a child. J Dermatol Venereol Leprol 2005; 71 (6): 432-433

  20. 20.Higgs JM, Wells RS. Chronic mucocutaneous candidiasis: New approaches to treatment. Br J Dermatol 1973; 89: 179-190

  21. Ro B. Chronic mucocutaneous candidosis. J Dermatol 1988; 27: 457-462

  22. Fajita M, Danno K, Ohno S. Two cases of diaper area granuloma of the adult. J Dermatol 1991; 18: 671-675

  23. Hassan G. Terbinafine effectiveness in ketoconazole resistant mucocutaneous candidiasis in polyglandular autoimmune syndrome type 1. J Assoc Physicians India 2003; 51: 323-326

  24. 24.Dupont B. An epidemiological review of systemic fungal infections. J Mycol Med 2002; 12: 163-173

  25. Seebacher C. Candida in dermatology. Mycoses 1999; S1: 63-67

  26. 26.Kalffa VC. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency Ann Allergy Asthma. Immunol 2003; 90 (2): 259-64

  27. Ginter G, Rieger E, Stefan H. Granulomatous panniculitis caused by Candida albicans: A case presenting with multiple leg ulcers. J Am Acad Dermatol 1993; 28: 315-317

  28. Heimadahl A, Nord C. Oral yeast infections in immunocompromised and seriously diseased patients. Acta Odontol Scand 1990; 48: 77-84

  29. 29.Horshmaneimo M, Kai K, Virolainen M. Immunologic features of chronic granulomatous mucocutaneous candidiasis before and after treatment with transfer factor ARC. Dermatology 1979; 115: 169-178

  30. Santos P, Oleastro M, Galicchio M. Infecciones fúngicas en pacientes pediátricos con enfermedad granulomatosa crónica. Rev Iberoam Micol 2000; 17: 6-9

  31. Liu J. Histopathologic and scanning electron microscope examination of the nail and hair in chronic mucocutaneous candidiasis. J Am Acad Dermatol 2003; 49 (2): 154-156

  32. Jorgensen E. Histopathology, immunology and serology of oral yeast infections. Diagnosis of oral candidosis. Acta odontol Scand 190 (48): 37-43

  33. Venkita J, Andavolu H, Chin T. Granulomatous inflammation in the acquired immune deficiency syndrome. Am J Clin Pathol 1985; 84: 598-602

  34. Lilic D. Deregulated production of protective cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasis. Infect Immunol 2003; 71 (10): 5690-5699

  35. Robert R, Senté JM. Physiopathologie des candidosis. J Mycol Med 1995, 5: 145-166

  36. Frank O. Candida species and virulence. Features 1994; 190 (60): 313-318

  37. Dupont B, Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol 1988; 26: 67-71

  38. Albrech C, Martínez J. Sensibilidad al fluconazol y la anfotericina B en cepas de Candida provenientes de aislamientos clínicos. Rev Iberoam Micol 1998; 15: 298-299

  39. Budtz-Jorgensen E. Etiology, pathogenesis, therapy and prophylaxis of oral yeast infections. Acta Odontol Scand 1990; 48: 61-69

  40. 40.Campos J, Franco G, Hamdan J. Phenotypic and genotypic identification of Candida sp. isolated from hospitalized patients. Rev Iberoam Micol 2004; 21: 24-28

  41. Fontenay C, Lavielle B, Linas D. Comparaison statistique de deux méthodes d’évaluation de la activité antifongique. J Mycol Med 1996; 6: 129-132

  42. Ceballos A, Gaitán L. Resistencia in vitro a los antifúngicos en Cándida albicans de pacientes infectados por el VIH con o sin candidiosis [¿candidosis o candidiasis?] oral. Rev Iberoam Micol 1999; 16: 194-197

  43. Drohuet E, Dupont B. Laboratory and clinical assessment of ketoconazole in deep seated mycoses. Am J Med. 1983; 74: 30-47

  44. 44.Drouhet E, Dupont B. Chronic mucocutaneous candidosis and other superficial and systemic mycoses successfully treated with ketoconazole. Rev Infect Dis. 1980; 2: 606-619




2020     |     www.medigraphic.com